Skip to content

To study the effect of high-frequency Repetitive transcranial magnetic stimulation (rTMS) in cognitive function and predominantly negative symptoms in person suffering from schizophrenia in a randomized sham controlled double blind trial.

To study the effect of high-frequency Repetitive transcranial magnetic stimulation (rTMS) in cognitive function and predominantly negative symptoms in person suffering from schizophrenia in a randomized sham controlled double blind trial. - STN

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019099
Enrollment
100
Registered
2019-05-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Schizophrenia with negative symptoms of PANSS equal or more than 15

Interventions

Intervention1: rTMS: repetitive transcarnial magnetic stimulation. Will be used to treat randomized arms. Active arm will receive Real rTMS and control arm will receive Sham rTMS Control Intervention1

Sponsors

DEPARTMENT OF SCIENCE AND TECHNOLOGY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Schizophrenia having PANSS negative symptoms with score of 15 or more. Willing to participate in the study Should be able to meet ICD10 criteria

Exclusion criteria

Exclusion criteria: 1.Individuals diagnosed by the investigator with the following conditions (current unless otherwise stated): Comorbid ICD-10 Axis I diagnosis, particularly current affective disorder including Depressive Disorder, Bipolar Affective Disorder; substance abuse or dependence within the past year (except nicotine and caffeine)as assessed on M.I.N.I. History of seizure, TIA, dementia, pregnancy, any movement disorder, metallic implant within or near the head, history of rTMS intervention, implanted medicated pumps,any cardiac illness

Design outcomes

Primary

MeasureTime frame
Cognitive symptoms improvement in: immediate & delayed memory -auditory and visual perceptual motor and executive functioning Verbal N Back test Negative symptoms assessment changes Timepoint: Baseline, 20th day post rTMS, 30th day post rtms(1month)

Secondary

MeasureTime frame
Global clinical improvement on Clinical global impression Depression as on the Calgary depression scale for schizophrenia. Assessment of above parameters at 1 month follow up to assess whether the effects last longer. Timepoint: Baseline, 20th day post rTMS, 30th day post rtms(1month)

Countries

India

Contacts

Public ContactDr Nand Kumar

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

nandkm2001@gmail.com01126593236

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026